Filana Therapeutics, Inc.

What they do

Filana develops simufilam, an oral small molecule designed to modulate the protein filamin A, which the company believes contributes to seizures in Tuberous Sclerosis Complex (TSC). The company has no approved products and no product revenue; it is preclinical/clinical-stage and has financed operations through stock offerings and interest income. Its prior Alzheimer's disease Phase 3 program was fully phased out in Q2 2025.

Revenue drivers

• Product revenue — None; the company has no approved products and has never generated product revenue.
• Collaborative agreements — Historically a source of financing, but no active collaboration revenue is disclosed in the excerpts.
• Interest on cash balances — Interest earned on cash and cash equivalents of $82.7 million as of June 30, 2026 is a financing source, not an operating business.
• Equity financings — Operations have been funded primarily through public and private stock offerings, including the 2024 warrant distribution and a $50 million ATM established in November 2025.

Recent performance

Q2 2026 net loss was $8.6 million, or $0.18 per share, versus a $44.2 million loss in Q2 2025. R&D expense fell 35% year-over-year to $3.3 million due to the Alzheimer's program phase-out, and G&A fell 85% to $6.1 million because Q2 2025 included a $31.25 million securities litigation loss contingency. Cash was $82.7 million at June 30, 2026, down from $95.5 million at year-end 2025, with no debt. First-half 2026 net cash used in operations was $12.7 million, below previous guidance.

Strategy

The company is focused on simufilam for TSC-related epilepsy and is engaging with the FDA to lift a full clinical hold on its planned proof-of-concept trial. It continues TSC community engagement, including sponsoring the 2026 TSC World Conference in Aurora, Colorado, July 30-August 1, 2026, and published Eilat XVIII proceedings in Epilepsia on the preclinical rationale. It holds an exclusive worldwide license from Yale (February 26, 2025) covering certain intellectual property for simufilam in TSC-related epilepsy and other indications, subject to milestones and royalties. It also has nine issued U.S. patents on simufilam with expirations from 2029 to 2040.

Risks

• FDA clinical hold — The FDA has placed a full clinical hold on the planned clinical studies, which may delay development and harm the business.
• No approved products — The company has no approved products and may never achieve regulatory approval or commercial success.
• Single candidate dependence — The company is heavily dependent on simufilam; failure in clinical development or regulatory approval would prevent product revenue.
• Securities litigation — A $31.25 million securities litigation loss contingency was recorded in Q2 2025 and paid into escrow on July 23, 2026, subject to final court approval.

Outlook

Management expects second-half 2026 net cash used in operations of $11 to $15 million, plus the $31.25 million litigation settlement funding already paid into escrow. The company estimates unrestricted cash at year-end 2026 in a range from $36 to $40 million. It continues to work with the FDA to address the clinical hold and prepare for future development of simufilam.